Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the double-blind, U.S. Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.

On the 834-patient trial's primary endpoint, atogepant significantly reduced mean monthly migraine or probable migraine headache days from baseline over 12 weeks by 4 at the once-daily 10 mg dose (p=0.0236), 3.8 at the once-daily 30 mg dose (p=0.039), 3.6 at the once-daily 60 mg dose (p=0.039), 4.2 at the twice-daily 30 mg dose (p=0.0034) and 4.1 at the twice-daily 60 mg dose (p=0.0031) vs. 2.9 for placebo...